IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Immunovant, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$27.62+0.89 (+3.33%)
Close on Oct 19, 2026
- Market cap
- $5.68B
- P/E (TTM)
- –
- Dividend yield
- –
Immunovant statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Immunovant | Industry median |
|---|---|---|
| Market Cap | $5.70B | $166.30M |
| Enterprise Value | $4.91B | $88.19M |
| PB Ratio | 7.76 | 2.03 |
| P/TBV Ratio | 7.76 | 2.29 |
Income (trailing twelve months)
| Measure | Immunovant | Industry median |
|---|---|---|
| Pretax Income | -$538.92M | -$14.34M |
| Net Income | -$538.22M | -$22.46M |
| EPS (Diluted) | -$2.82 | -$0.83 |
Returns
| Measure | Immunovant | Industry median |
|---|---|---|
| Return on Equity (ROE) | -80.1% | -53.2% |
| Return on Assets (ROA) | -71.1% | -40.9% |
Balance sheet
| Measure | Immunovant | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $797.80M | $61.43M |
| Net Cash (Debt) | $797.80M | $15.35M |
| Net Cash Per Share | $3.86 | $0.66 |
| Equity (Book Value) | $735.39M | $49.09M |
| Book Value Per Share | $3.56 | $1.37 |
| Tangible Book Value | $735.39M | $23.52M |
| Working Capital | $734.08M | $76.81M |
Financial position
| Measure | Immunovant | Industry median |
|---|---|---|
| Current Ratio | 7.27 | 3.34 |
| Quick Ratio | 6.82 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Immunovant | Industry median |
|---|---|---|
| Operating Cash Flow | -$414.30M | -$12.35M |
Efficiency
| Measure | Immunovant | Industry median |
|---|---|---|
| Profits Per Employee | -$1.71M | -$703.34K |
| Employee Count | 315 | 74 |
Dividends and yields
| Measure | Immunovant | Industry median |
|---|---|---|
| Earnings Yield | -9.43% | -23.3% |
Shares
| Measure | Immunovant | Industry median |
|---|---|---|
| Shares Outstanding | 206,553,000 | 58,127,000 |
| Shares Change (YoY) | 21.1% | 10.9% |
| Shares Change (QoQ) | 1.14% | 0.54% |
| Float | 88,033,900 | 49,136,700 |
| Shares Held by Insiders | 57.4% | 11.6% |
| Shares Held by Institutions | 53.5% | 59.4% |
Taxes
| Measure | Immunovant | Industry median |
|---|---|---|
| Income Tax | -$698.00K | $79.87K |
Scores
| Measure | Immunovant | Industry median |
|---|---|---|
| Altman Z-Score | 27.15 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Immunovant's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.